Health
DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19 – News-Medical.Net
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3…
RedHill Biopharma Ltd. (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.
Opaganib is a novel, orally-administered sphingosine…
-
General13 hours agoFarmers develop ‘autofill’ tech so agricultural robots can operate around the clock
-
Noosa News19 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General16 hours agoTrump mulling whether to fire US Fed chair Powell
-
Noosa News19 hours agoNowhere is growing like this corner of Queensland. It’s changing the political game